Inflammatory and antimicrobial diseases are a major burden for the society today and fighting them is a national and WHO strategic priority. Nowadays, most of the treatments available on the market to fight inflammatory diseases are anti-inflammatory drugs, such as corticosteroids or immunomodulators that lack cellular specificity and lead to numerous side effects. However, in addition to suppressing undesired inflammation and reducing disease progression, these drugs lessen the immune system protective functions. Furthermore, treating infectious diseases is more and more challenging, due to the increase of microbial resistance to antimicrobial drugs.
Psoriasis is a lifelong chronic inflammatory disease with no curative treatments available, where inflammation and angiogenic processes and bacterial infection play a major role in its development. Thus, specifically controlling the inflammatory and angiogenic processes without compromising the ability of the body to combat infections is an essential feature of the treatment of psoriasis.
In this study, we characterized a new peptide isolated from the Mexican tree frog, Pachymedusa dacnicolor that exhibits at the same time, anti-inflammatory, anti-angiogenic, and antimicrobial properties. Indeed, in vitro, this peptide specifically inhibits the development of angiogenesis, kills immune cells without compromising the integrity of non-immune cells and kills Gram-positive and Gram-negative bacteria. In vivo, this peptide reduces disease progression in the preclinical imiquimod-induced murine model of psoriasis, by inhibiting the formation of neo vessels and psoriatic skin. Thus, our peptide could be a promising drug in the treatment of psoriasis.
Funded by Fronteras de la Ciencia/CONACYT, Mexico